MENU
BNR
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

BNR stock forecast, quote, news & analysis

Burning Rock Biotech Ltd is a cancer diagnostics company... Show more

BNR
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for BNR with price predictions
Oct 01, 2026

BNR's Stochastic Oscillator is staying in overbought zone for 10 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for BNR moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 21 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

BNR broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 03, 2026. You may want to consider a long position or call options on BNR as a result. In 63 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.

The Moving Average Convergence Divergence (MACD) for BNR just turned positive on September 03, 2026. Looking at past instances where BNR's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.

BNR moved above its 50-day moving average on September 03, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +23.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNR advanced for three days, in 187 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

The Aroon Indicator entered an Uptrend today. In 97 of 116 cases where BNR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.417) is normal, around the industry mean (72.578). P/E Ratio (0.000) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (1.741) is also within normal values, averaging (9.775).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. BNR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 20.78B. The market cap for tickers in the group ranges from 27 to 4.39T. MKYSF holds the highest valuation in this group at 4.39T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was -3%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 47%. ADVB experienced the highest price growth at 10%, while BIAF experienced the biggest fall at -22%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was -28% and the average quarterly volume growth was 9%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 59
Price Growth Rating: 42
SMR Rating: 78
Profit Risk Rating: 91
Seasonality Score: 20 (-100 ... +100)
View a ticker or compare two or three
BNR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a company, which engages in the investment of medical fields and specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology

Industry MedicalSpecialties

Industry
N/A
Address
No. 5, Xingdao Ring Road North
Phone
+86 2034037871
Employees
667
Web
https://www.brbiotech.com
BNR's Stochastic Oscillator is staying in overbought zone for 10 days